Tag: tissue factor

AACR 2026: Emerging Antibody-Drug Conjugates for the Treatment of Solid Tumors (Part 1)

Recent advances in antibody-drug conjugate (ADC) technology have enabled the development of highly potent, tumor-targeted therapeutics with improved efficacy and safety. Sutro Biopharma, leveraging its site-specific and cell-free protein synthesis platform, has reported robust preclinical data for its pipeline of next-generation ADCs at the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026.

The U.S. Food & Drug Administration (FDA) has provided clearance of the Investigational New Drug (IND) application for a Phase 1 Tiffany-01 study (NCT06597721) evaluating ADCE-T02 (previously known as AMT 754; see Drugmap), a novel antibody-drug conjugate being developed by Adcendo.

Danish Adcendo and Shanghai-based Multitude Therapeutics have signed a licensing agreement for the development of ADCE-T02, a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF), a transmembrane glycoprotein expressed by subendothelial cells and fibroblasts, that plays an important role in hemostasis regulation.

The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for tisotumab vedotin (Tivdak®; Genmab and Pfizer) for the treatment of patients with recurrent or metastatic cervical cancer.

An ongoing, phase 1 dose-escalation study investigating XB002, Exelixis’ next-generation tissue factor-targeting antibody-drug conjugate (ADC) for the treatment of patients with advanced solid tumors, has shown promising results.

Preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (Tivdak®; Seagen and Genmab) as a monotherapy in patients...

MRG004A, an antibody-drug conjugate targeting human tissue factor to treat solid tumors, has entered clinical trials in the United States.  The investigational agent, being...

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tisotumab vedotin-tftv (Tivdak™; Seagen/GenMab; previously known as HuMax®-TF-ADC), a first-in-class and only approved...

Each year more than 13,500 women in the United States are diagnosed with invasive cervical cancer and approximately 4,200 will die of the disease....